CYC is an established company making its entry into the U.S market and they have already secured partnerships with the most significant players like the VA and one of the largest healthcare providers HCA. In other countries growth is stagnant, but the USA represents an untapped growth opportunity with more potential than most other markets combined. Also, the company is making an effort to broaden its market through clinical trials for new indications (Beyond PE strategy) and so far looks promising. They've also given guidance on future installations, so I feel confident that my investment will see growth within the next 18 months. It might not be the 10x return some investors chase, but doubling my investment is good enough for me
On the other hand, I’m not sure if 4DMedical’s CT:VQ will achieve adoption at a faster rate than its existing "game-changing" technologies (such as CT LVAS). If CT:VQ fails to gain traction quickly, it could add to the company’s financial challenges.
I also hold positions in both companies and feel that CYC is currently the safer investment for me.
CYC Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)